BPG is committed to discovery and dissemination of knowledge
Articles in Press
6/2/2026 7:42:29 AM | Browse: 5 | Download: 0
Publication Name World Journal of Hepatology
Manuscript ID 121954
DOI 10.4254/wjh.121954
Country China
Category Pharmacology & Pharmacy
Manuscript Type Basic Study
Article Title Poria in Fuling Zexie decoction for treating metabolic dysfunction-associated steatotic liver disease: Underlying mechanisms and key bioactive substances
Manuscript Source Unsolicited Manuscript
All Author List Yu-Xuan Tao, Di-Hong Gong, Huan Yang, Peng-Quan Wang, Yan-Mei Tang, Qi-Di Zhou, Yan-Yan Wang, Yue Zhang, Wei-Dong Chen, Jie Yu and Xing-Xin Yang
Funding Agency and Grant Number
Corresponding Author Xing-Xin Yang, College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Yunnan Key Laboratory of Southern Medicine Utilization, No. 1076 Yuhua Road, Kunming 650500, Yunnan Province, China. yxx78945@163.com
Key Words Effective substances; Fuling Zexie decoction; Lipid metabolism; Liver disease; Mechanism; Poria; Metabolic dysfunction-associated steatotic liver disease
Core Tip This study clarified the specific contribution of Poria (PR) as the “sovereign” drug in Fuling Zexie decoction (FZD) for metabolic dysfunction-associated steatotic liver disease. We confirmed that PR plays an irreplaceable role and its removal significantly weakened the therapeutic efficacy of FZD. The superior effects of FZD were attributed to diverse active components (six derived from PR), the specific regulation of five metabolic pathways (biotin, ascorbate/aldarate, alanine/aspartate/glutamate, inositol phosphate, and galactose metabolism), and 148 differential metabolites. Additionally, incorporating PR dregs enhanced antioxidant and anti-inflammatory activities, indicating that water-insoluble polysaccharides are key bioactive constituents.
Citation Tao YX, Gong DH, Yang H, Wang PQ, Tang YM, Zhou QD, Wang YY, Zhang Y, Chen WD, Yu J, Yang XX. Poria in Fuling Zexie decoction for treating metabolic dysfunction-associated steatotic liver disease: Underlying mechanisms and key bioactive substances. World J Hepatol 2026; In press
Received
2026-04-09 03:21
Peer-Review Started
2026-04-09 03:23
First Decision by Editorial Office Director
2026-04-16 07:57
Return for Revision
2026-04-17 05:55
Revised
2026-05-10 09:27
Publication Fee Transferred
2026-05-12 06:32
Second Decision by Editor
2026-06-02 02:42
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-06-02 07:42
Articles in Press
2026-06-02 07:42
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com